⌘K

Login Start Free

Home/Filings/4/0001415889-25-004509

4//SEC Filing

LaBarre Michael J. 4

Accession 0001415889-25-004509

CIK 0001159036other

View on SEC.gov Company Profile

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 6:42 PM ET

Size

24.7 KB

Accession

0001415889-25-004509

Insider Transaction Report

Form 4

Period: 2025-02-15

HALOZYME THERAPEUTICS, INC.HALO

LaBarre Michael J.

VP, Product Development

Transactions

Exercise/Conversion
Common Stock
2025-02-15+3,386→ 177,142 total
Exercise/Conversion
Common Stock
2025-02-16+20,891→ 196,729 total
Tax Payment
Common Stock
2025-02-16$58.29/sh−8,721$508,347→ 188,008 total
Exercise/Conversion
Common Stock
2025-02-16+6,112→ 194,120 total
Exercise/Conversion
Restricted Stock Units
2025-02-16−4,263→ 8,526 total
Exercise: $0.00→ Common Stock (4,263 underlying)
Tax Payment
Common Stock
2025-02-15$58.29/sh−1,304$76,010→ 175,838 total
Tax Payment
Common Stock
2025-02-16$58.29/sh−3,103$180,874→ 191,017 total
Exercise/Conversion
Common Stock
2025-02-16+4,263→ 195,280 total
Tax Payment
Common Stock
2025-02-16$58.29/sh−2,164$126,140→ 193,116 total
Exercise/Conversion
Restricted Stock Units
2025-02-15−3,386→ 0 total
Exercise: $0.00→ Common Stock (3,386 underlying)
Exercise/Conversion
Performance Stock Units
2025-02-16−20,891→ 0 total
Exercise: $0.00→ Common Stock (20,891 underlying)
Exercise/Conversion
Restricted Stock Units
2025-02-16−6,112→ 6,112 total
Exercise: $0.00→ Common Stock (6,112 underlying)

Footnotes (6)

[F1]The reported disposition of 1,304 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F2]The reported disposition of 8,721 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F3]The reported disposition of 3,103 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F4]The reported disposition of 2,164 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
[F5]This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
[F6]This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer.

Documents

1 file

4
form4-02182025_110228.xmlPrimary

Issuer

HALOZYME THERAPEUTICS, INC.

CIK 0001159036

Entity typeother

Related Parties

1

filerCIK 0001507174

Filing Metadata

Form type: 4
Filed: Feb 17, 7:00 PM ET
Accepted: Feb 18, 6:42 PM ET
Size: 24.7 KB

View on SEC.gov